GlassScriptPhysician profile
Michael Elias
NPI 1710410766
$543.48
in general payments reported to CMS, 2019-2025
7 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $338 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.49 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $247.43 | 2024 | Fruzaqla |
| Daiichi Sankyo INC. | $157.67 | 2025 | Enhertu |
| Pfizer INC. | $48.59 | 2024 | |
| Aveo Pharmaceuticals, INC. | $24.74 | 2024 | |
| Janssen Biotech, INC. | $23.91 | 2025 | Erleada |
| Genentech USA, INC. | $23.77 | 2025 | Venclexta |
| Azurity Pharmaceuticals, INC. | $17.37 | 2024 | Vivimusta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Elias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.